title: Role of VEGF/VEGFR in the pathogenesis of leukemias and as treatment             targets (Review).
abstract: Angiogenesis plays an important role in solid tumor growth, progression             and metastasis. Evidence suggests that the progression of hematolymphoid malignancies             also depends on the induction of new blood vessel formation under the influence             of acute leukemia, myelodysplastic syndromes, myeloproliferative neoplasms, multiple             myeloma and lymphomas. The vascular endothelial growth factor (VEGF) is the most             important proangiogenic agent that activates receptors on vascular endothelial             cells and promotes blood vessel regeneration. It has been demonstrated that VEGF/VEGF             receptor (VEGFR) expression is upregulated in several types of hematolymphoid             tumor cells accompanied with angiogenesis. The levels of VEGF/VEGFR are correlated             with the treatment, relapse and prognosis of hematolymphoid tumors. In order for             VEGF family and their receptors as antiangiogenic targets to treat solid tumors,             several antiangiogenic agents targeting VEGF-related pathways have been used for             the treatment of hematolymphoid malignancies in clinical trials. The results demonstrate             a promising therapeutic intervention in multiple types of hematolymphoid tumors.             This review aims to summarize recent advances in understanding the role of VEGF             and angiogenesis in leukemias, mainly focusing on their upstream transcriptors,             downstream targets and the correlation of VEGF/VEGFR with the treatment, relapse             or prognosis of leukemia. The progress of VEGF and its receptors as attractive             targets for therapies are also discussed in clinical application.
authors.affiliation: Key Laboratory for Tumor Immunology and Traditional Chinese Medicine Immunology, Key Laboratory for Rare and Uncommon Diseases of Shandong Province, Department of Hemato-Oncology, Institute of Basic Medicine, Shandong Academy of Medical Sciences, Key Laboratory of Ministry of Health for Biotech-Drug, Key Laboratory for Modern Medicine and Technology of Shandong Province, Jinan, Shandong, P.R. China.
authors.forename: Guanhua
authors.initials: G
authors.lastname: Song
authors.forename: Yanmei
authors.initials: Y
authors.lastname: Li
authors.forename: Guosheng
authors.initials: G
authors.lastname: Jiang
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D006801:Humans; D007938:Leukemia / Q000188:drug therapy* / Q000378:metabolism; D058990:Molecular Targeted Therapy; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D040262:Receptors, Vascular Endothelial Growth Factor / Q000235:genetics / Q000378:metabolism*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000378:metabolism*
chemical_list: D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D040262:Receptors, Vascular Endothelial Growth Factor